What we still don’t know about weight-loss drugs

Unfortunately, the company found that the drug did not appear to delay the progression of Alzheimer’s disease in the volunteers who took it.

The news came as a huge disappointment to the research community. “It was kind of crushing,” says Drucker. That’s despite the fact that, deep down, he wasn’t expecting a “clear win.” Alzheimer’s disease has proven notoriously difficult to treat, and by the time people get a diagnosis, a lot of damage has already taken place.

But he is one of many…